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ABSTRACT
OBJECTIVE: To analyze the patterns and legal requirements of 
methylphenidate consumption.
METHODS: We conducted a cross-sectional study of the data from 
prescription notification forms and balance lists of drugs sales – psychoactive 
and others – subject to special control in the fifth largest city of Brazil, in 
2006. We determined the defined and prescribed daily doses, the average 
prescription and dispensation periods, and the regional sales distribution in 
the municipality. In addition, we estimated the costs of drug acquisition and 
analyzed the individual drug consumption profile using the Lorenz curve.
RESULTS: The balance lists data covered all notified sales of the drug 
while data from prescription notification forms covered 50.6% of the 
pharmacies that sold it, including those with the highest sales volumes. 
Total methylphenidate consumption was 0.37 DDD/1,000 inhabitants/day. 
Sales were concentrated in more developed areas, and regular-release tablets 
were the most commonly prescribed pharmaceutical formulation. In some 
regions of the city, approximately 20.0% of the prescriptions and dispensation 
exceeded 30 mg/day and 30 days of treatment.
CONCLUSIONS: Methylphenidate was widely consumed in the municipality 
and mainly in the most developed areas. Of note, the consumption of 
formulations with the higher abuse risk was the most predominant. Both its 
prescription and dispensation contrasted with current pharmacotherapeutic 
recommendations and legal requirements. Therefore, the commercialization 
of methylphenidate should be monitored more closely, and its use in the 
treatment of behavioral changes of psychological disorders needs to be 
discussed in detail, in line with the concepts of the quality use of medicines.
DESCRIPTORS: Methylphenidate, administration & dosage. 
Drugs of Special Control. Psychotropic Drugs. Drug Utilization. 
Pharmacoepidemiology.
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Methylphenidate is a central nervous system stimulant 
recommended for the treatment of attention-deficit/
hyperactivity disorder (ADHD), a neurobehavioral 
disorder affecting school-going children and adoles-
cents. It is also prescribed for narcolepsy, depression, 
obesity, and cognitive disorders.14 Methylphenidate 
is the most common psychostimulant medicine 
worldwide, with production increasing from 2.8 tons (t) 
in 1990 to 63.2 t in 2012.a,b Commercialization of meth-
ylphenidate began in Brazil in 1998, and its produc-
tion increased almost 3-fold between 2009 and 2011.c
RESUMO
OBJETIVO: Analisar padrões e requisitos legais do consumo de metilfenidato.
MÉTODOS: Estudo transversal realizado em Belo Horizonte, MG, em 2006. 
Foram analisados dados de notificações de receitas de metilfenidato e de 
balanços de vendas de medicamentos – psicoativos e outros – sujeitos a controle 
especial. Determinou-se a dose diária definida, a dose diária prescrita, o período 
médio de prescrição e de dispensação, bem como a distribuição regional das 
vendas desse medicamento no município. Foram estimados, ainda, os gastos 
com a aquisição do medicamento e analisado o perfil de consumo individual 
do fármaco por meio da Curva de Lorenz.
RESULTADOS: Os dados dos balanços mensais de comercialização de 
psicotrópicos cobriram toda a comercialização notificada do fármaco, enquanto 
aqueles coletados nas notificações de receita cobriram 50,6% das farmácias que 
o comercializaram, incluindo aquelas de maior volume de venda. O consumo de 
metilfenidato foi 0,37 DDD/1.000 habitantes/dia. As vendas concentraram-se 
em áreas mais desenvolvidas e as formulações farmacêuticas de liberação não 
controlada foram as mais prescritas. A prescrição e a dispensação com dosagens 
> 30 mg/dia e período de tratamento > 30 dias apresentaram valores em torno 
de 20,0% em algumas regiões da cidade.
CONCLUSÕES: O consumo de metilfenidato apresentou-se elevado no 
município, maior em áreas mais favorecidas economicamente e predominando 
o consumo de formulações com maior risco de abuso. Tanto a prescrição 
quanto a dispensação apresentaram características não compatíveis com as 
recomendações farmacoterapêuticas e determinações legais. O controle de 
venda do fármaco deve ser monitorado e a farmacoterapia das alterações 
comportamentais amplamente rediscutida em concordância com os conceitos 
do uso de medicamentos com qualidade.
DESCRITORES: Metilfenidato, administração & dosagem. 
Medicamentos de Controle Especial. Psicotrópicos. Uso de 
Medicamentos. Farmacoepidemiologia.
INTRODUCTION
The consumption of methylphenidate, as measured 
by defined daily doses (DDD) per 1,000 inhabitants/
day, increased between 2009 and 2012.14,19 In 2009, 
the levels were 0.39 in the United Kingdom, 1.49 in 
Spain, and 9.30 in the United States (US) and 0.68 in 
the United Kingdom, 2.82 in Spain, 7.94 in the US, 
and 14.72 in Switzerland by 2012, showing a distin-
guished pattern of increased consumption. In Denmark, 
consumption increased in the period of 1995 to 2011 
recording up to 6.7 DDD per 1,000 inhabitants/day 
according to a national survey.19 However, information 
regarding methylphenidate consumption in Brazil is 
a International Narcotics Control Board. Comments on the reported statitics on psychotropic substance for 2009. Vienna; 2010. 
b International Narcotics Control Board. Comments on the reported statistics on psychotropic substance for 2012. Vienna; 2013.
c Agência Nacional de Vigilância Sanitária. Panorama dos dados do Sistema Nacional de Gerenciamento de Produtos Controlados: um 
sistema para o monitoramento de medicamentos no Brasil. Bol Farmacoepidemiol SNGPC. 2012 [cited 2014 Jun 23];1(2). Available from: 
http://www.anvisa.gov.br/sngpc/boletins/2011/boletim_sngpc_2edatualizada.pdf
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scarce, although it is now available nationally following 
the implementation of an electronic system to record 
prescription and sales data for narcotic or psychotropic 
substances. Although the consumption of methylphe-
nidate has increased nationally, trends in the pattern 
of its consumption are unclear in Belo Horizonte, in 
Southeastern Brazil.20
The consumption of methylphenidate for the treatment 
of ADHD is controversial in the literature. Different 
diagnostic criteria, with narrower or broader defini-
tions of ADHD, increases the possibility of misdiag-
noses, which may in turn result in excessive prescrip-
tion and consumption.2,18,20 In addition, the pharmaco-
logical approach for the treatment of ADHD without 
educational and psychotherapeutic intervention has 
been questioned,3,13,25 including its relationship to meth-
ylphenidate misuse among children.d Higher frequen-
cies of methylphenidate consumption in privileged 
socieconomic environments5 may also hide sociocul-
tural issues of underuse and overuse in disadvantaged 
and privileged populations, respectively. Over a decade 
ago, an article in the Brazilian literature argued that less 
rigorous control of the sales of methylphenidate was 
necessary to improve access and lower the risk of stig-
matization of the patient, on the basis of the conclusion 
that there was a low risk of dependency and that adverse 
reactions to this medicine were nonserious.10 However, 
in another scenario, the nonmedical (off-label) use of 
methylphenidate for recreation or to improve academic 
performance has highlighted the possibility of abuse.7,17
Brazilian legislation restricts the prescription and 
dispensation of narcotic or psychotropic substances.e 
Prescriptions require special documentation prior to 
dispensation. The prescription notification form is used 
to authorize the commercialization of substances on 
specific lists of medicines that are subject to special 
control: List A (yellow), for narcotic and psychotropic 
substances that are most restricted, followed by Lists B 
(blue) and C (white). The yellow and blue notifications 
are retained by pharmacies at the time of the purchase. 
The prescription notification form for methylphenidate 
belongs to List A, and has a recommended maximum 
treatment of 30 days, consistent for this substance class. 
Additionally, balance lists of drugs – psychoactive and 
others – subject to special control (BMPO) is used to 
record all purchases and sales controlled by the munic-
ipal surveillance bureau information, including the 
pharmacy, the responsible pharmacist, and the medicine 
prescribed and dispensed. Each pharmacy is required to 
submit this information to the county health authorities 
periodically and the process has been controlled by an 
online record system through the national surveillance 
bureau since 2007.
Considering that the assessment of clinical conditions 
that justifies methylphenidate prescription is difficult, 
and that the drug also has abuse potential, concerns 
have been raised regarding the rationality of methyl-
phenidate consumption. This study aimed to analyze 
the patterns and legal requirements of methylphenidate 
consumption in the fifth most inhabited city of Brazil. 
Specifically, we assessed the prescription, dispensation, 
and commercialization of methylphenidate, exploring 
the patterns of use according to established indica-
tors. This is the first study to consider the commer-
cial patterns of the prescription and dispensation of 
methylphenidate in a city in a large and heterogeneous 
country like Brazil.
METHODS
We conducted a cross-sectional study regarding the 
data for methylphenidate prescription and dispensa-
tion extracted from BMPO and the prescription noti-
fication forms in Belo Horizonte between January 1 
and December 31, 2006. The city, which is the capital 
of Minas Gerais, is located in the most economically 
developed region of the country, with approximately 
2.4 million people (12.0% of the state and 1.3% of 
the national population). It has a high rate of literacy 
and piped water, and the average monthly income is 
about 10.0% higher than the national average. The 
municipality is divided into nine districts: Barreiro, 
Central-South, East, Northeast, Northwest, North, West, 
Pampulha, and Venda Nova. Each district represents a 
health sector responsible for the planning and imple-
mentation of different healthcare interventions.
The Prometheus Project is a research line of the Centro 
de Estudos do Medicamento (CEMED – Center of 
Medicines Studies in English) of the Universidade 
Federal de Minas Gerais, which focuses on the clinical, 
epidemiological, social, and anthropological perspec-
tives of methylphenidate consumption. The project was 
created following published scientific and legal recom-
mendations for the prescription and dispensation of 
methylphenidate in Brazil.
We extracted the following information from BMPOs 
for methylphenidate: brand name, formulation and 
package, dose unit, and the amount sold/dispensed. 
We calculated the totality of methylphenidate commer-
cialization in total milligrams and in Defined Daily 
Doses (DDD) in milligrams/1,000 inhabitants/day. 
d European Medicines Agency Press Office. European Medicines Agency makes recommendations for safer use of Ritalin and other 
methylphenidate-containing medicines in the EU [press-release]. London; 2009 [cited 2014 Aug 11]. Doc. Ref. EMEA/22315/2009. Available 
from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500014589.pdf 
e Agência Nacional de Vigilância Sanitária. Portaria nº 344, de 12 de maio de 1998. Aprova o Regulamento Técnico sobre substâncias e 
medicamentos sujeitos a controle especial [Approves the Technical Regulation on substances and medicinal products subject to special control]. 
Brasília (DF): 1998 [cited 2014 May 27]. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html
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The recommended DDD of methylphenidate by the 
World Health Organization is 30 mg/day for adults, 
but DDD for children has not been established. 
Commercialization of methylphenidate was charac-
terized by pharmaceutical formulation (regular-release 
tablets versus controlled-release tablets) and treat-
ment costs were estimated by assessing the number of 
commercialized units on the basis of the average unit 
price for the corresponding prescriptions, using prices 
informed by ANVISA (Brazilian National Surveillance 
Bureau) for 2006. All costs in the study are indicated 
in US dollars (USD).
Prescription notifications were used to characterize 
prescription and dispensation patterns of methylphe-
nidate (amount per user and per gender, the total cost 
of the treatment per year, the medical specialty of 
the prescribers, the total amount of methylphenidate 
prescribed and dispensed in the number of packages 
and in terms of the pharmaceutical formulation, and 
the duration of treatment in days, both prescribed and 
dispensed). We estimated the prescribed daily dose 
(PDD) using the average doses.
We used the Lorenz curve, an analytical technique 
described by Hallas & Støvring11 to study the skewness of 
methylphenidate consumption. The curve was expected 
to be diagonal line if all users took similar doses, while 
a skewed pattern would cause the curve to skew toward 
the upper left corner.10,11 Users were ranked in descending 
order by methylphenidate consumption (obtained by 
multiplying the PDD by the treatment duration) to esti-
mate the Lorenz curve. The cumulative percentage of 
methylphenidate used was then calculated and plotted on 
the y-axis, against the cumulative percentage of persons 
on the x-axis, and skewness analyzed by calculating 
the cumulated first percentile (1-percentile) and fiftieth 
percentile (50-percentile). The cumulated 1-percentile 
and 50-percentile for methylphenidate consumption is 
defined as the share of total methylphenidate consumed 
by 1.0% and 50.0%, respectively, of the most heavily 
consuming users. High values for any of these measures, 
assumed at levels of 15.0% and 90.0% for the 1-percen-
tile and 50-percentile respectively, suggest skewed 
consumption. Thus, a Lorenz 1-percentile of  > 15.0% 
implied the existence of heavy users, whereas a Lorenz 
50-percentile of > 90.0% indicated widespread occa-
sional or sporadic consumption.10,11
We used three indicators to assess the quality of prescrip-
tion and dispensation according to previously reported 
parameters and on the basis of Brazilian sanitary legis-
lation, as follows: the proportion of prescriptions with a 
dosage of  > 30 mg/day (number of prescriptions with 
dosage of > 30 mg/day/total prescriptions); the propor-
tion of prescriptions with duration of treatment longer 
than the recommended period (number of prescriptions 
lasting > 30 days/total prescriptions), and, the propor-
tion of prescriptions dispensed that are for more than the 
recommended treatment duration (number of prescrip-
tions dispensed for > 30 days of treatment/total prescrip-
tions). These indicators were dichotomized, as follows: 
daily dosage (> 30 mg; ≤ 30 mg), prescribed treatment 
duration (> 30 days; ≤ 30 days), and dispensed treatment 
duration (i.e., > 30 days; ≤ 30 days). The indicators were 
compared according to administrative districts using 
the Pearson Chi-square test with significance values of 
P value < 0.05.
Stata software version 10.1 (Stata Corp, College 
Station, TX) was used for all statistical analyses.
The study was approved by the Research Ethics 
Committee of the Universidade Federal de Minas 
Gerais (ETIC147/06). Managerial personnel of the 
participating pharmacies (pharmaceutical or commer-
cial) received a document containing project details 
before signing an informed consent form.
RESULTS
Of the 79 pharmacies that commercialized methylphe-
nidate in Belo Horizonte in the year of 2006, 5 contrib-
uted to 97.1% of all sales, and 1 pharmacy was respon-
sible for 36.8% of total sales. More than 85.0% of meth-
ylphenidate commercialized was concentrated in the 
East, Central-South, and West regions, accounting for 
27,157 packages or 8,456,860 mg, which was equiva-
lent to 657,230.37 USD (Table 1).
In total, 31,869 drug packages were sold (9,611,280 mg, 
725,078.58 USD). The more frequently commercial-
ized pharmaceutical formulation was regular-release 
tablets (84.4%). Total methylphenidate consumption 
was 0.37 DDD/1,000 inhabitants/day.
In total, 6,611 methylphenidate prescriptions were 
analyzed from 40 participating pharmacies. These 
accounted for 50.6% of all pharmacies reporting on 
the commercialization of methylphenidate in 2006, and 
comprise the five that were responsible for the largest 
volume of sales. It was possible to identify the medical 
specialty of the prescribing physicians in 92.7% of 
the cases. The majority were neurologists (48.4%), 
followed by psychiatrists (42.4%), and pediatricians 
(5.2%). The remaining (4.0%) prescriptions were from 
professionals of other medical specialties.
The prescription corresponded to 3,068 users. They 
received 1-15 drug prescriptions during the period of 
the study, each equivalent to 240.00 USD/user/year, 
or approximately 1.5 times the minimum wage. The 
majority of the users were men (72.6%). Treatment 
doses lower than the DDD were observed in 66.9% 
of prescriptions: 20 mg/day in 46.7% and 10 mg/
day in 20.2%. In 15.6% of the cases, 30 mg/day was 
the prescribed dose, whereas doses of  > 30 mg/day 
were prescribed in 17.6% of the cases. Of the total 
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of all prescriptions, 0.8% had a recommended dose 
of > 60 mg/day. Lorenz curve analysis (Figure) did 
not show the presence of a significant proportion of 
heavy users or sporadic users (1-percentile = 7.8%; 
50-percentile = 82.9%; respectively).
PDD was estimated to be 23.9 mg/day [standard devia-
tion (SD) 12.8; range 10-240 mg/day] with an average 
treatment period of 31 days. The maximum prescribed 
treatment period was 600 days. The dispensation was 
conducted for an average 29 days, and for a maximum 
of 540 days. Approximately 85.0% of the prescriptions 
were dispensed for up to 30 days (Table 2). The distribu-
tion of PDD by administrative district showed a similar 
pattern of approximately 20 mg/day. Exceptions were 
noted in the East and Northeast districts where PDDs 
was slightly higher and equal to 26.1 mg/day (SD = 13.6) 
and 25.4 mg/day (SD = 12.5), respectively (Table 3).
Significant regional differences between the daily 
dosage and dispensation were observed. The East, 
Northeast, and Central-South districts showed higher 
proportions of prescriptions with a daily dosage of 
> 30 mg (Table 4). The pattern of prescribed treat-
ment duration did not vary among regions, but signifi-
cant differences were noted in the Pampulha and the 
Central-South districts showing higher prescription 
rates of notifications with > 30 days of treatment.
DISCUSSION
The estimated consumption of methylphenidate in Belo 
Horizonte in 2006 was comparable with two European 
countries, i.e., Spain (1.26 DDD/1,000 inhabitants/
day) and Ireland (0.65 DDD/1,000 inhabitants/day), 
and one Latin American country, i.e., Chile (0.53 
DDD/1,000 inhabitants/day also in 2006).f In general, 
most prescriptions recommended a dose below the DDD, 
with 20 mg/day being the most commonly prescribed. 
Although the notifications included no information 
on the clinical indications, others studies suggest that 
the drug is mainly used to treat ADHD in children and 
adolescents.15,23,24 The confidence in the therapeutic value 
of methylphenidate in this treatment has resulted in a 
significant increase in its consumption over recent years. 
However, this increase may also be a consequence of 
over-diagnosis due diagnostic difficulties and failure to 
comply with established diagnostic criteria.1,9,12,21
The Lorenz curve indicated that were was not a signifi-
cant prevalence of either heavy or sporadic users, which 
is similar to that observed by others authors.15,19 This 
correlates with the values for the use of methylpheni-
date for ADHD in Denmark between 2010 and 2011 
(1-percentile = 6.1% and 50-percentile = 84.4%).19 
However, we found significant differences in the 
daily dose prescribed and dispensed between districts, 
with more prescriptions of > 30 mg/day in the East, 
Northeast, and Central-South districts. These districts 
include markedly wealthier city areas, and the observed 
differences may represent social determinants of meth-
ylphenidate consumption, reinforcing the need to 
investigate diagnostic aspects related to methylpheni-
date prescription and dispensation. Furthermore, these 
higher doses raise the risk of adverse effects, such as 
anxiety, headache, insomnia, tachycardia, and anorexia.
Prescription and dispensation of methylphenidate was 
concentrated in the East and Central-South adminis-
trative districts. The association between increased 
dispensing and better quality of life in those regions 
indicates two possible interdependent factors: a regional 
concentration of pharmacy networks dominating 
the drug market and socioeconomic issues of access 
to health care services and medications. Although 
we cannot exclude differences in diagnostic criteria 
adopted by physicians in different areas, it was notice-
able that the percentage of pharmacies commercial-
izing methylphenidate was low, with just five being 
Table 1. Methylphenidate commercialization by administrative district according to the balance list of sales of psychoactive 
and other drugs subjected to special control (BMPO). Belo Horizonte, MG, Southeastern Brazil, 2006. (N = 79)
Region Amount (mg) % Packages (units) %
East 3,952,720 41.1 12,744 40.0
Central-South 2,790,240 29.0 9,571 30.0
West 1,713,900 17.8 4,842 15.2
Northeast 745,500 7.8 2,902 9.1
Northwest 215,020 2.2 968 3.0
Barreiro 114,100 1.2 516 1.6
Venda Nova 71,900 0.7 294 0.9
Pampulha 7,900 0.1 32 0.1
Total 9,611,280 31,869
BMPO: balance lists of sales of psychoactive and other drugs subjected to special control
f International Narcotics Control Board. Statistics on psychotropic substance for 2006. Vienna; 2007. 
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responsible for most sales. This identifies an alarming 
pharmacoepidemiological reality that deserves the 
attention of health authorities.
It is important mentioning that methylphenidate is not 
currently incorporated by the Brazilian Unified Health 
System (SUS). Therefore, a court order is required 
for this medicine be provided free of charge. This 
may explain the concentration of sales in the East and 
Central-South districts where the household income per 
capita is higher. These results reinforce the relevance 
of the role of socioeconomic factors in the prescription 
and use of methylphenidate, as was also reported in the 
US.8 Inequitable access to methylphenidate may there-
fore affect diagnosis and treatment, linking poverty with 
poorer mental health care.
Regular-release tablets were the most frequently 
commercialized pharmaceutical formulation, which 
is similar to the results of other studies.23 This type of 
formulation has the disadvantage of a more complex 
medication regimen that can compromise treatment 
adherence. Moreover, regular-release tablets may 
also facilitate drug abuse since methylphenidate has 
the capacity of methylphenidate to induce euphoric 
effects similar to cocaine.16 In this context, controlled-
release formulations offer lower abuse potential and 
a more convenient dosing schedule, despite being 
more expensive.6
The prescribed and dispensed methylphenidate treat-
ment durations did not agree with national legislation. 
Approximately 20.0% and 15.0% of the total of the 
prescribed and dispensed methylphenidate, respec-
tively, exceeded the acceptable treatment period of 30 
days. There was a regional difference in drug dispen-
sation, which should alert drug-regulatory agencies 
when planning drug control activities, especially 
when consolidating information on a computerized 
Table 2. Prescribed daily dose, average prescribed treatment duration and dispensation of methylphenidate, according to the 
Prescription Notification Form Belo Horizonte, MG, Southeastern Brazil, 2006. (N = 6,611)
Variable PDD (mg) Average duration of the treatment (days) Dispensation (average, in days)
Average (standard deviation) 23.9 (12.8) 31.4 (19.0) 29.1 (16.0)
Minimum 10 4 3
Maximum 240 600 540
PDD: prescribed daily dose
Table 3. Distribution of dispensed prescriptions and of prescribed daily doses by administrative district, according to the 
Prescription Notification Forms. Belo Horizonte, MG, Southeastern Brazil, 2006.
Region N % PDD Standard deviation
Central-South 3,579 54.1 23.8 13.3
East 1,175 17.8 26.1 13.6
Northeast 1,015 15.4 25.4 12.5
Northwest 240 3.6 19.7 7.8
Pampulha 239 3.6 21.0 8.7
Venda Nova 132 2.0 19.6 8.0
Barreiro 126 1.9 19.2 8.9
West 105 1.6 20.1 8.7
Total 6,611 100 23.9 12.8
PDD: prescribed daily dose
a The straight line indicates the hypothetical scenario 
of homogenous prescriptions among users; the curved 
line indicates the real prescribed drug proportion 
(1-percentile = 7.8% and 50-percentile = 82.9%)
Figure. Lorenz curve for methylphenidate prescription,a 
according to the prescription notification forms. Belo 
Horizonte, MG, Southeastern Brazil, 2006. (N = 3,068 users).
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monitoring system. Indeed, this could readily be 
monitored by the new online system for the control of 
psychotropic sales.
Our results are based on commercialization and 
prescription data, representing estimates of the true 
consumption of methylphenidate in the investigated 
population.22 The data were collected in a large city, 
similar to many others in terms of population and 
development characteristics. Therefore, our results 
may be regarded as an important source of parameters 
for the question investigated. Prescription notifications 
were analyzed for 50.6% of the commercial pharma-
cies reporting to dispense methylphenidate in BMPO. 
According to this data, 70.0% and 60.0% of pharma-
cies in the East and Central-South districts, respectively, 
submitted their notifications of prescription for inclu-
sion in this study. These regions accounted for approxi-
mately 70.1% of methylphenidate commercialization in 
the city, including the five highest-dispensing pharma-
cies (97.1% of sales between them). Thus, we believe 
our data allows analysis of a representative picture of 
the prescription and dispensing practices in the area.
The data sources did not provide any diagnosis-
related information and precluded assessment of the 
sociodemographic profile of users, such as education 
and income, which limited our analyses. However, 
the study was based on the information required by 
health legislation in the country, conferring consis-
tency to the data collected. Furthermore, this is the 
first study to characterize the patterns of commer-
cialization, prescribing, and dispensation of methyl-
phenidate in Brazil. Our results suggest that there are 
regional differences in methylphenidate consumption, 
with higher access in the more economically devel-
oped areas. However, these were based in sales data 
only and did not assess the habitation region at the 
individual level. Consequently, this evidence should 
be interpreted with caution.
Methylphenidate was often prescribed in pharma-
ceutical formulations with higher risk of abuse and 
less likely to encourage adherence. Furthermore, the 
regulations regarding the prescription and dispensa-
tion of methylphenidate are not consistently applied. 
Health authorities, physicians, and pharmacists need 
to exercise greater caution regarding the use of meth-
ylphenidate. This drug therapy is nowadays consid-
ered a standard treatment for ADHD, but besides the 
fact that it has a not well-known biological bases, it 
has relevant psychosocial and cultural components. 
Therefore, treatment with methylphenidate may be 
intensely discussed in order to establish the rationality 
and safety of its use. Authorities must improve the 
control and supervision of methylphenidate commer-
cialization and implement interventions to promote 
good prescription practices. We believe that the less 
strict drug control proposed by Carlini et al4 (2003), 
to facilitate access and avoid stigmatization, is highly 
questionable given our findings.
Table 4. Prescription and dispensation of methylphenidate by dose and treatment duration in different administrative districts, 
according to the Prescription Notification Forms. (N = 6,611)
Region
Prescription Dispensation
  
Dose (%) Duration (%) Duration (%)
   
> 30 mg ≤ 30 mg > 30 days ≤ 30 days > 30 days ≤ 30 days
Central-South 17.1 82.9 19.7 80.3 16.2 83.8
East 24.3 75.7 19.4 80.6 14.1 85.9
Northeast 21.6 78.4 18.5 81.5 14.2 85.8
Northwest 4.6 95.4 18.8 81.2 6.7 93.3
Pampulha 7.9 92.1 23.0 77.0 19.7 80.3
Venda Nova 2.3 97.7 18.2 81.8 14.4 85.6
Barreiro 7.1 92.9 21.4 78.6 5.6 94.4
West 2.9 97.1 22.9 77.1 12.4 87.6
p < 0.001a p = 0.80a p < 0.001a
a Pearson Chi-square test
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